Preventing OsteoPorosis in Spinal Cord Injury (POPSCI) Study—Early Zoledronic Acid Infusion in Patients with Acute Spinal Cord Injury

• Published in: Calcified tissue international 2024-11, Vol.115 (5), p.611-623
• Main Authors: Kumar, Shejil, Doyle, Jean, Wood, Cameron, Heriseanu, Roxana, Weber, Gerard, Nier, Lianne, Middleton, James W., March, Lyn, Clifton-Bligh, Roderick J., Girgis, Christian M.
• Format: Article
• Language: English
• Subjects: Adult; Biochemistry; Biomedical and Life Sciences; Bone Density - drug effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - therapeutic use; Bone loss; Bone mineral density; Cell Biology; Cohort Studies; Collagen; Dual energy X-ray absorptiometry; Endocrinology; Female; Femur; Hip; Humans; Knee; Life Sciences; Male; Middle Aged; Original Research; Orthopedics; Osteoporosis; Osteoporosis - drug therapy; Osteoporosis - prevention & control; SOST protein; Spinal cord injuries; Spinal Cord Injuries - complications; Spinal Cord Injuries - drug therapy; Tibia; Zoledronic acid; Zoledronic Acid - administration & dosage; Zoledronic Acid - therapeutic use
• ISSN: 1432-0827; 0171-967X; 1432-0827
• DOI: 10.1007/s00223-024-01292-3

Accelerated sub-lesional bone loss is common in the first 2–3 years after traumatic spinal cord injury (TSCI), particularly in the distal femur and proximal tibia. Few studies have explored efficacy of antiresorptives for acute bone loss prevention post-TSCI, with limited data for knee bone mineral density (BMD) or beyond two years follow-up. An open-label non-randomized study was performed at Royal North Shore Hospital and Royal Rehab Centre, Sydney between 2018 and 2023. An ‘acute interventional cohort’ ( n  = 11) with TSCI (duration ≤ 12-weeks) received a single infusion of 4 mg zoledronic acid (ZOL) at baseline. A ‘chronic non-interventional cohort’ ( n  = 9) with TSCI (duration 1–5-years) did not receive ZOL. All participants underwent baseline and 6-monthly blood tests (including CTx and P1NP) and 12-monthly DXA BMD scans (including distal femur and proximal tibia). Participants were predominantly Caucasian and male (mean age 38.4 years). At baseline, the ‘acute’ cohort had higher serum CTx, P1NP and sclerostin concentrations, while the ‘chronic’ cohort had lower left hip and knee BMD. Majority with acute TSCI experienced an acute phase reaction after ZOL (9/11; 82%). In the acute cohort, left hip BMD fell by mean ~ 15% by 48 months. Left distal femoral and proximal tibial BMD declined by mean ~ 6–13% at 12 months and ~ 20–23% at 48 months, with a tendency towards greater BMD loss in motor-complete TSCI. A single early ZOL infusion in acute TSCI could not attenuate rapidly declining hip and knee BMD. Prospective controlled studies are required to establish the optimal strategy for preventing early bone loss after acute TSCI.